Kazia Therapeutics Limited American Depositary Shares - KZIA STOCK NEWS

Kazia Therapeutics Limited (NASDAQ: KZIA) received a deficiency notification from Nasdaq on December 9, 2022, for not meeting the minimum bid price requirement of US$ 1.00 per share, as per Nasdaq Listing Rule 5550(a)(2). The deficiency, effective from December 8, 2022, does not impact the company's operations immediately, and its shares will continue trading on Nasdaq-CM. Kazia has until June 7, 2023, to regain compliance by maintaining the required share price for 10 consecutive business days. The notice does not affect its listing on the ASX under KZA.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the publication of positive preclinical data for EVT801, a clinical-stage cancer drug candidate. The research, led by scientists at Evotec SE and the University Cancer Institute of Toulouse, demonstrates EVT801's potency as a selective inhibitor of VEGFR3, outperforming standard treatments in animal models. The compound shows promise in combination with immune checkpoint inhibitors. Currently, EVT801 is in a phase I clinical trial for advanced solid tumors, with initial data expected in 1H 2023.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the presentation of final data from its phase II study of paxalisib for newly diagnosed glioblastoma at the Society for Neuro-Oncology annual meeting in Tampa, FL, from Nov. 17-20, 2022. Professor Patrick Wen will present the findings, with a session focused on clinical trials. Additionally, Professor Matt Dun will share research on paxalisib's impact on diffuse midline gliomas. This meeting follows earlier presentations at ASCO and ESMO in 2022, highlighting the ongoing significance of paxalisib in brain cancer treatment.

Kazia Therapeutics reported its Q123 cash flow, revealing a period dominated by challenges faced by paxalisib in the GBM AGILE study. Despite this setback, there was clinical progress in pediatric brain cancers and brain metastases. The company ended the quarter with a cash balance of AU$5.3m (c US$3.4m) and expects this to last until the end of CY22. R&D expenses totaled AU$4.3m, and with the completion of enrollment for the GBM study, future expenditures are projected to decrease significantly.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from its collaboration with the Huntsman Cancer Institute, showing that paxalisib is effective against preclinical models of metastatic melanoma. Dr. Gennie Parkman presented data indicating that paxalisib shows promise as a monotherapy and even greater efficacy in combination with existing therapies. With melanoma affecting about 100,000 Americans annually and a high mortality rate, further clinical trials for paxalisib in this area are anticipated in the near future, aiming to address unmet medical needs.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the international expansion of its phase II study of paxalisib, aimed at treating diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs). This study, sponsored by the Pacific Pediatric Neuro-Oncology Consortium, has recently opened two sites in Australia, marking its first trial in the country. The trial combines paxalisib with ONC201 and is currently active at nine sites in the U.S. and two in Australia, with plans for further international expansion. Initial data is anticipated in 2023.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced that CEO Dr. James Garner will present at the 24th Annual Global Investment Conference in New York from September 12-14, 2022. The presentation will highlight three positive data read-outs from Kazia's oncology programs in 2022 and discuss upcoming developments. The company's management team will also hold one-on-one meetings with institutional investors during the conference. Kazia is focused on developing treatments for aggressive brain cancers, including their lead program, paxalisib.

Kazia Therapeutics Limited (NASDAQ: KZIA) has announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be presented at the European Society for Medical Oncology (ESMO) annual congress in Paris, France from September 9-13, 2022. The presentation will detail findings previously highlighted at the ASCO Annual Meeting in June 2022. Professor John de Groot from the University of California, San Francisco will deliver the presentation, covering pharmacokinetics and pharmacodynamics.

Kazia Therapeutics reported busy FY22 results focusing on its oncology pipeline. The year featured positive data from preclinical and clinical programs, especially in childhood brain cancers. However, the lead asset paxalisib did not advance to Stage 2 in the Phase III GBM AGILE study for glioblastoma multiforme. The company's net cash at year-end stood at US$5.3m, needing an estimated US$50m more to reach break-even. Valuation remains at US$146.6m, with per basic ADR dropping to US$9.42 due to share count increase.